China Oncology ›› 2025, Vol. 35 ›› Issue (1): 21-29.doi: 10.19401/j.cnki.1007-3639.2025.01.003
• Specialist' Commentary • Previous Articles Next Articles
ZHANG Zhiyue1,2(), HE Huijing1(
), SHAN Guangliang1, LIN Yansong3(
)
Received:
2024-12-04
Revised:
2025-01-23
Online:
2025-01-30
Published:
2025-02-17
Contact:
HE Huijing, LIN Yansong
Share article
CLC Number:
ZHANG Zhiyue, HE Huijing, SHAN Guangliang, LIN Yansong. Research progress in epidemiology and risk factors of thyroid cancer[J]. China Oncology, 2025, 35(1): 21-29.
Tab. l
The key risk factors for the incidence of thyroid cancer"
Factor | Specific finding |
---|---|
Physiological factors | Gender, age: thyroid cancer incidence is significantly higher in women worldwide, especially during reproductive years[ |
Lifestyle and environmental factors | Ionizing radiation: exposure to ionizing radiation is a well-established risk factor for thyroid cancer[ |
Obesity: both overweight and obesity may increase the risk of developing thyroid cancer[ | |
Iodine intake: long-term excessive or insufficient iodine intake can lead to thyroid cancer[ | |
Others: psychological factors such as negative emotions, stress, and anxiety may increase the risk of thyroid cancer[ | |
Genetic factors | RET, BRAF, RAS, p53: mutations in proto-oncogenes, mismatch repair genes, and inactivation of tumor suppressor genes may lead to thyroid cancer[ |
[1] | International Agency for Research on Cancer. World Cancer Report[R]. Lyon, 2014. |
[2] | 赫捷, 魏文强. 2021中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2023. |
HE J, WEI W Q. Annual report of cancer registries in China 2021[M]. Beijing: People’s Medical Publishing House, 2023. | |
[3] | 刘志艳, 刘书佚, 王馨培, 等. 第5版WHO甲状腺滤泡源性肿瘤分类解读[J]. 中华病理学杂志, 2023, 52(1): 7-12. |
LIU Z Y, LIU S Y, WANG X P, et al. Interpretation of the 5th edition WHO classification of follicular cell derived thyroid tumors[J]. Chin J Pathol, 2023, 52(1): 7-12. | |
[4] | 董芬, 张彪, 单广良. 中国甲状腺癌的流行现状和影响因素[J]. 中国癌症杂志, 2016, 26(1): 47-52. |
DONG F, ZHANG B, SHAN G L. Distribution and risk factors of thyroid cancer in China[J]. China Oncol, 2016, 26(1): 47-52. | |
[5] | 梁岭. 甲状腺癌临床特征分布与发病相关因素研究[D]. 合肥: 安徽医科大学, 2019. |
LIANG L. Research on the distribution of clinical characteristics and related risk factors of thyroid cancer[D]. Hefei: Anhui Medical University, 2019. | |
[6] | 杨雷, 王宁. 甲状腺癌流行病学研究进展[J]. 中华预防医学杂志, 2014, 48(8): 744-748. |
YANG L, WANG N. Research progress in the epidemiology of thyroid cancer[J]. Chin J Prev Med, 2014, 48(8): 744-748. | |
[7] | KITAHARA C M, SOSA J A. Understanding the ever-changing incidence of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(11): 617-618. |
[8] | PIZZATO M, LI M M, VIGNAT J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020[J]. Lancet Diabetes Endocrinol, 2022, 10(4): 264-272. |
[9] | AHMEDIN JEMAL DVM P. Cancer statistics, 2024[J]. CA A Cancer J Clin, 2024, 74(1): 12-49. |
[10] | AHN H S, KIM H J, WELCH H G. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis[J]. N Engl J Med, 2014, 371(19): 1765-1767. |
[11] | WILD C P, WEIDERPASS E, STEWART B W. World cancer report: cancer research for cancer prevention[J]. 2020 |
[12] | KILFOY B A, ZHENG T Z, HOLFORD T R, et al. International patterns and trends in thyroid cancer incidence, 1973-2002[J]. Cancer Causes Control, 2009, 20(5): 525-531. |
[13] |
LIM H, DEVESA S S, SOSA J A, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA, 2017, 317(13): 1338-1348.
doi: 10.1001/jama.2017.2719 pmid: 28362912 |
[14] | Globocan: global cancer statistics[EB/OL]. [2024-12-20]. https://gco.iarc.fr. |
[15] | YU G P, LI J C, BRANOVAN D, et al. Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups[J]. Thyroid, 2010, 20(5): 465-473. |
[16] | WANQING CHEN PHD M, MPH R Z, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2): 115-132. |
[17] | 张思维, 郑荣寿, 孙可欣, 等. 2016年中国恶性肿瘤分地区发病和死亡估计: 基于人群的肿瘤登记数据分析[J]. 中国肿瘤, 2023, 32(5): 321-332. |
ZHANG S W, ZHENG R S, SUN K X, et al. Estimation of cancer incidence and mortality in different geographic areas of China in 2016: analysis based on population-based cancer registry data[J]. China Cancer, 2023, 32(5): 321-332. | |
[18] | 杨志杰, 王璐, 钱云, 等. 2009—2019年江苏省肿瘤登记地区甲状腺癌发病趋势和年龄变化特征分析[J]. 中国肿瘤, 2024, 33(12): 991-998. |
YANG Z J, WANG L, QIAN Y, et al. Trends of incidence and diagnostic age of thyroid cancer in cancer registration areas of Jiangsu province from 2009 to 2019[J]. China Cancer, 2024, 33(12): 991-998. | |
[19] | 罗亭亭, 孟迪, 张华, 等. 2010—2017年青岛市居民甲状腺癌发病与死亡分析[J]. 中华肿瘤防治杂志, 2019, 26(17): 1231-1236. |
LUO T T, MENG D, ZHANG H, et al. Analysis of thyroid cancer incidence and death among Qingdao residents from 2010 to 2017[J]. Chin J Cancer Prev Treat, 2019, 26(17): 1231-1236. | |
[20] | 雷林, 尚庆刚, 刘维耿, 等. 深圳市2001—2015年甲状腺癌发病现状和趋势分析[J]. 中国肿瘤, 2019, 28(7): 504-508. |
LEI L, SHANG Q G, LIU W G, et al. Incidences and epidemiologic trends of thyroid cancer in Shenzhen, 2001-2015[J]. China Cancer, 2019, 28(7): 504-508. | |
[21] | 杜瑞, 梁楠, 孙辉. 儿童及青少年甲状腺癌诊疗进展[J]. 中国普通外科杂志, 2019, 28(11): 1431-1436. |
DU R, LIANG N, SUN H. Progress of diagnosis and treatment of thyroid carcinoma in children and adolescents[J]. Chin J Gen Surg, 2019, 28(11): 1431-1436. | |
[22] | LI M M, DAL MASO L, PIZZATO M, et al. Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013-17 in 63 countries worldwide: a population-based study[J]. Lancet Diabetes Endocrinol, 2024, 12(11): 824-836. |
[23] | KITAHARA C M. The growing global burden of thyroid cancer overdiagnosis[J]. Lancet Diabetes Endocrinol, 2024, 12(11): 780-782. |
[24] | VACCARELLA S, FRANCESCHI S, BRAY F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis[J]. N Engl J Med, 2016, 375(7): 614-617. |
[25] | BARREA L, GALLO M, RUGGERI R M, et al. Nutritional status and follicular-derived thyroid cancer: an update[J]. Crit Rev Food Sci Nutr, 2021, 61(1): 25-59. |
[26] |
LI N, DU X L, REITZEL L R, et al. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008[J]. Thyroid, 2013, 23(1): 103-110.
doi: 10.1089/thy.2012.0392 pmid: 23043274 |
[27] | LIU J, XU T M, MA L, et al. Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J]. Front Oncol, 2021, 11: 593479. |
[28] |
NASH S H, LANIER A P, SOUTHWORTH M B. Occurrence of endocrine and thyroid cancers among Alaska native people, 1969-2013[J]. Thyroid, 2018, 28(4): 481-487.
doi: 10.1089/thy.2017.0408 pmid: 29439613 |
[29] |
MEMON A, ROGERS I, PAUDYAL P, et al. Dental X-rays and the risk of thyroid cancer and meningioma: a systematic review and meta-analysis of current epidemiological evidence[J]. Thyroid, 2019, 29(11): 1572-1593.
doi: 10.1089/thy.2019.0105 pmid: 31502516 |
[30] |
BAKER S R, BHATTI W A. The thyroid cancer epidemic: is it the dark side of the CT revolution?[J]. Eur J Radiol, 2006, 60(1): 67-69.
pmid: 16787731 |
[31] | FRANCHINI F, PALATUCCI G, COLAO A, et al. Obesity and thyroid cancer risk: an update[J]. Int J Environ Res Public Health, 2022, 19(3): 1116. |
[32] |
KITAHARA C M, MCCULLOUGH M L, FRANCESCHI S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies[J]. Thyroid, 2016, 26(2): 306-318.
doi: 10.1089/thy.2015.0319 pmid: 26756356 |
[33] |
BURRAGE L C, MCLEOD D S A, JORDAN S J. Obesity and thyroid cancer risk[J]. Curr Opin Endocrinol Diabetes Obes, 2023, 30(5): 244-251.
doi: 10.1097/MED.0000000000000825 pmid: 37410455 |
[34] |
SCHMID D, RICCI C, BEHRENS G, et al. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis[J]. Obes Rev, 2015, 16(12): 1042-1054.
doi: 10.1111/obr.12321 pmid: 26365757 |
[35] | AVGERINOS K I, SPYROU N, MANTZOROS C S, et al. Obesity and cancer risk: emerging biological mechanisms and perspectives[J]. Metabolism, 2019, 92: 121-135. |
[36] | ALMQUIST M, JOHANSEN D, BJÖRGE T, et al. Metabolic factors and risk of thyroid cancer in the metabolic syndrome and cancer project (Me-Can)[J]. Cancer Causes Control, 2011, 22(5): 743-751. |
[37] |
LAURBERG P, PEDERSEN I B, KNUDSEN N, et al. Environmental iodine intake affects the type of nonmalignant thyroid disease[J]. Thyroid, 2001, 11(5): 457-469.
doi: 10.1089/105072501300176417 pmid: 11396704 |
[38] |
吴恋, 于健春, 康维明, 等. 碘营养状况与甲状腺疾病[J]. 中国医学科学院学报, 2013, 35(4): 363-368.
doi: 10.3881/j.issn.1000-503X.2013.04.001 |
WU L, YU J C, KANG W M, et al. Iodine nutrition and thyroid diseases[J]. Acta Acad Med Sin, 2013, 35(4): 363-368.
doi: 10.3881/j.issn.1000-503X.2013.04.001 |
|
[39] | 崔玉山, 刘洪亮. 甲状腺癌流行病学特征和碘营养关系研究进展[J]. 环境卫生学杂志, 2020, 10(2): 212-217. |
CUI Y S, LIU H L. Epidemiological characteristics of thyroid cancer and its association with iodine nutrition[J]. J Environ Hyg, 2020, 10(2): 212-217. | |
[40] | KIM H J, PARK H K, BYUN D W, et al. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area[J]. Eur J Nutr, 2018, 57(2): 809-815. |
[41] | 陈芳, 吴凯, 徐明星, 等. 基于病例对照研究的甲状腺癌危险因素的meta分析[J]. 中华地方病学杂志, 2017, 36(4): 250-256. |
CHEN F, WU K, XU M X, et al. Meta-analysis of risk factors of thyroid cancer: base on case-control study[J]. Chin J Endem, 2017, 36(4): 250-256. | |
[42] | JUNG S K, KIM K, TAE K, et al. The effect of raw vegetable and fruit intake on thyroid cancer risk among women: a case-control study in South Korea[J]. Br J Nutr, 2013, 109(1): 118-128. |
[43] |
ROCHE A M, FEDEWA S A, SHI L L, et al. Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer[J]. Cancer, 2018, 124(8): 1780-1790.
doi: 10.1002/cncr.31252 pmid: 29409119 |
[44] | 郑维晖, 龚巍巍, 陆凤, 等. 甲状腺癌相关基因突变和表观遗传学研究进展[J]. 中华流行病学杂志, 2017, 38(11): 1579-1583. |
ZHENG W H, GONG W W, LU F, et al. Progress in research of thyroid carcinoma related gene mutation and epigenetics[J]. Chin J Epidemiol, 2017, 38(11): 1579-1583. | |
[45] | 宋创业, 严丽, 孟艳林, 等. 甲状腺癌发生发展及预后的相关影响因素[J]. 中华普通外科学文献(电子版), 2020, 14(1): 72-75. |
SONG C Y, YAN L, MENG Y L, et al. Related factors of occurrence, development and prognosis of thyroid cancer[J]. Chin Arch Gen Surg Electron Ed, 2020, 14(1): 72-75. | |
[46] | KIM H, KIM H I, KIM S W, et al. Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea[J]. Endocrinol Metab (Seoul), 2018, 33(2): 287-295. |
[47] | TANG J N, KONG D G, CUI Q X, et al. Racial disparities of differentiated thyroid carcinoma: clinical behavior, treatments, and long-term outcomes[J]. World J Surg Oncol, 2018, 16(1): 45. |
[48] | ELISEI R, MOLINARO E, AGATE L, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4 187 patients from a single Italian institution to answer this question[J]. J Clin Endocrinol Metab, 2010, 95(4): 1516-1527. |
[49] | KIM J Y, MYUNG J K, KIM S, et al. Prognosis of poorly differentiated thyroid carcinoma: a systematic review and meta-analysis[J]. Endocrinol Metab (Seoul), 2024, 39(4): 590-602. |
[50] | 张磊, 董云伟, 胡神保, 等. 美国癌症联合委员会甲状腺癌分期系统(第8版)修订对甲状腺乳头状癌分期的影响[J]. 中国癌症杂志, 2018, 28(7): 491-496. |
ZHANG L, DONG Y W, HU S B, et al. The impact of American Cancer Joint Committee revised thyroid cancer staging system (8th edition) on staging of papillary thyroid carcinoma[J]. China Oncol, 2018, 28(7): 491-496. | |
[51] |
SHTEINSHNAIDER M, MUALLEM KALMOVICH L, KOREN S, et al. Reassessment of differentiated thyroid cancer patients using the eighth TNM/AJCC classification system: a comparative study[J]. Thyroid, 2018, 28(2): 201-209.
doi: 10.1089/thy.2017.0265 pmid: 29256827 |
[52] |
KAZAURE H S, ROMAN S A, SOSA J A. The impact of age on thyroid cancer staging[J]. Curr Opin Endocrinol Diabetes Obes, 2018, 25(5): 330-334.
doi: 10.1097/MED.0000000000000430 pmid: 30048260 |
[53] |
CHO J S, YOON J H, PARK M H, et al. Age and prognosis of papillary thyroid carcinoma: retrospective stratification into three groups[J]. J Korean Surg Soc, 2012, 83(5): 259-266.
doi: 10.4174/jkss.2012.83.5.259 pmid: 23166884 |
[54] |
ITO Y, MIYAUCHI A, KOBAYASHI K, et al. Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma[J]. Endocr J, 2014, 61(3): 205-213.
pmid: 24212880 |
[55] | 黄美玲, 李永平, 凌瑞. BRAF V600E基因突变与乳头状甲状腺癌淋巴结转移相关性的meta分析[J]. 中国肿瘤, 2017, 26(2): 145-151. |
HUANG M L, LI Y P, LING R. A meta-analysis on the correlation between BRAF V600E gene mutation and lymph nodes metastasis in papillary thyroid carcinoma[J]. China Cancer, 2017, 26(2): 145-151. | |
[56] |
FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883.
doi: S0923-7534(20)32555-2 pmid: 31987292 |
[57] | XING M Z, ALZAHRANI A S, CARSON K A, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1): 42-50. |
[58] | FEI-ZHANG D J, VERMA R, ARIMOTO R, et al. Social vulnerability association with thyroid cancer disparities in the United States[J]. Thyroid, 2024, 34(2): 225-233. |
[59] | MILLER D L, KAKAR S, JIANG L, et al. The U.S. Food and Drug Administration’s role in improving radiation dose management for medical X-ray imaging devices[J]. Br J Radiol, 2021, 94(1126): 20210373. |
[60] | DABELIĆ N, JUKIĆ T, FRÖBE A. Medullary thyroid cancer-feature review and update on systemic treatment[J]. Acta Clin Croat, 2020, 59(Suppl 1): 50-59. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd